Kilo Code | $8,000,000 | (Dec 11, 2025)
Empromptu.ai | $2,000,000 | (Dec 11, 2025)
Bobyard | $35,000,000 | (Dec 11, 2025)
Certified by Founder
Lodge
Ratio Therapeutics
start up
United States
- Boston, MA
- 02/12/2021
- Unknown
- $1,500,000
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.
Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
- Industry Pharmaceutical Manufacturing
- Website https://ratiotx.com/
- LinkedIn https://www.linkedin.com/company/rat
Radial | $50,000,000 | (Dec 11, 2025)
Channel3( YC S25) | $6,000,000 | (Dec 11, 2025)
D3 Bio | $108,000,000 | (Dec 11, 2025)
Sprouty | $550,000 | (Dec 11, 2025)
Fresco | $17,550,941 | (Dec 11, 2025)
BoodleBox | $5,000,000 | (Dec 11, 2025)
CoreOps.AI | $3,500,000 | (Dec 10, 2025)
BON Credit | $3,500,000 | (Dec 10, 2025)
Opine | $5,000,000 | (Dec 10, 2025)